Acute Porphyria Drug Database

Monograph

A10BJ01 - Exenatide
Propably not porphyrinogenic
PNP

Rationale
Hormone analogue not eliminated via Cyp metabolism. Side effects such as nausea, vomiting and diarrhoea may be potentially porphyrinogenic through reduction in carbohydrate intake.
Chemical description
Synthetic Exendin-2, a 39 amino acid peptide present in the saliva of the Gila monster lizard, which is a functional analog of Glucagon-Like Peptide-1.
Therapeutic characteristics
Exenatide is used in type 2 diabetes in combination with other anti-diabetics, when adequate glycaemic control has not been achieved by mono or dual therapy with metformin and a sulfonylurea. It is administered as a subcutaneous injection. The pharmacodynamics effects of exenatide, such as incretin-induced pancreatic liberation of insulin and subsequent tissue uptake of glucose, as well an inhibition of glucagon secretion, are theoretically anti-porphyrinogenic. Side effects such as nausea, vomiting and diarrhoea may be potentially porphyrinogenic through reduction in carbohydrate intake. Common adverse reactions of exenatide that may be confused with an acute porphyric attack are nausea, vomiting, constipation and abdominal discomfort.
Metabolism and pharmacokinetics
Nonclinical studies suggest that exenatide is predominantly eliminated via glomerular filtration and subsequent proteolytic break down of the peptide.
Similar drugs
Explore alternative drugs in similar therapeutic classes A10B / A10BJ or go back.

References

# Citation details PMID
*Scientific articles
1. Drug-drug interactions with glucagon-like peptide-1 receptor agonists.
Hurren KM, Pinelli NR. Ann Pharmacother. 2012 May; 46(5):710-7. Epub 2012 Apr 17.
22510669
*Drug reference publications
2. DrugBank. Exenatide.
*Drug interaction databases
3. Lexicomp Online. Martindale: The Complete Drug Reference. Exenatide. (Last updated: 10.02.12)
*Summary of Product Characteristics
4. The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). (Byetta).

Tradenames
This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.


Bydureon 2 mg poeder en oplosmiddel voor suspensie voor injectie met verlengde afgifte · Bydureon 2 mg poeder en oplosmiddel voor suspensie voor injectie met verlengde afgifte voor injectie in voorgevulde pen · Bydureon 2 mg suspensie met verlengde afgifte voor injectie in voorgevulde pen · Byetta, 10 microgram, oplossing voor injectie in voorgevulde pen · Byetta, 5 microgram, oplossing voor injectie in voorgevulde pen Bydureon · Bydureon 2 mg susp. inj. lib. prol. (pdr. + solv.) s.c. ser. pr?remplie flac. · Bydureon 2 mg susp. inj. lib. prol. (pdr. + solv.) s.c. stylo pr?rempli (cart.) · Bydureon 2 mg susp. inj. lib. prol. s.c. stylo pr?rempli (cart.) · Byetta · Byetta 10 ?g sol. inj. s.c. stylo pr?rempli · Byetta 5 ?g sol. inj. s.c. stylo pr?rempli Bydureon · Bydureon 2 mg Polvo y Disolvente Para Suspension Inyectable de Liberacion Prolongada · Bydureon 2 mg Polvo y Disolvente Para Suspension Inyectable de Liberacion Prolongada en Pluma Precargada · Byetta 10 Microgramos Solucion Inyectable en Pluma Precargada · Byetta 5 Microgramos Solucion Inyectable en Pluma Precargada Bydureon · Byetta BYDUREON 2 mg · Byetta · BYETTA 10?g/doza · BYETTA 5?g/doza Bydureon · Byetta Bydureon · Byetta Bydureon · Byetta Bydureon · Byetta Bydureon-2mg · Byetta Bydureon · Byetta Bydureon · Byetta Bydureon · Byetta
 
© NAPOS 2025
An unhandled error has occurred. Reload 🗙